Skip to content

Clinical study of fecal SDC2 / TFPI2 methylation combined with FIT in the detection of colorectal cancer and precancerous lesions

Clinical study of fecal SDC2 / TFPI2 methylation combined with FIT in the detection of colorectal cancer and precancerous lesions

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100049651
Enrollment
Unknown
Registered
2021-08-07
Start date
2021-08-15
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colonrectal cancer and precancerous lesions

Interventions

Gold Standard:colonoscopy/pathological diagnosis
combined&#32
with&#32

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients who need colonoscopy due to clinical diagnosis; 2. Willing to provide stool samples for FIT and DNA methylation testing; 3. Feces are provided within one month before and after colonoscopy.

Exclusion criteria

Exclusion criteria: 1. The samples may be contaminated by other samples during collection; 2. Combined with other malignant tumors, accompanied by other immune system diseases, and have received anti-tumor therapy such as radiotherapy/chemotherapy; 3. Fecal collection is obtained after endoscopic treatment of intestinal lesions; 4. Samples not preserved as required.

Design outcomes

Primary

MeasureTime frame
fecal SDC2 / TFPI2 methylation;stool occult blood test;colonoscopic results;pathologic results;

Countries

China

Contacts

Public ContactLin Rong

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

selinalin35@hotmail.com+86 15629180035

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026